Danish pharma company on cusp of international success

Diabetes drug could be headed to the US

Danish pharmaceutical company Danske Zealand Pharma has taken a major step in capitalising on its diabetes product Lyxumia.

The Glostrup-based firm and its partner Sanofi has received approval for a US application for the composite product Lixilan.

Lixilan is a mixture of Danske Zealand Pharma’s Lyxumia and the world’s best-selling insulin, Lantus Sanofios.

Now that the application has been officially processed, the company will find out in August if its product has been approved.

“The US approval of the application is an important milestone in the regulatory process for this new type of diabetes drug,” said Danske Zealand Pharma head Britt Meelby Jensen.

Profitable combination
Lyxumia is a GLP-1 analog that acts by stimulating the pancreatic production of insulin. It is the same type of product as Novo Nordisk’s Victoza, which earned 18 billion kroner in 2015.

Lyxumia as a single agent earned Dansk Zealand Pharma 21 million kroner in royalties in the first nine months of 2015.

READ MORE: Danish diabetes treatment among the best in Europe

The combination product Lixilan could help to considerably increase sales of Lyxumia.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.